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ABSTRACT Research in relation to the etiology of cervical cancer has made substantial progress in the last two
decades both in scientific and operational terms. In many countries, HPV is the most common sexually transmitted
infection (STI) and cervical cancer remains the second most common cancer among women worldwide. Although
high risk HPV infection has been identified as the primary etiological agent for cervical cancer, various co-factors
such as tobacco derived carcinogens, inhalation of air cotaminated through the combustion of coal and kitchen smoke
have also been reported to be associated with cervical cancer. Studies on HPV 16 E6 and E7 gene variations provide
evidence for the association of specific E6 gene variants with the risk of cervical cancer. While E6 variants may be
important in contributing to increased severity of cervical cancer, polymorphisms of other host cellular proteins,
such as p53 and p73, may also play an as yet undefined role in modulating the E6-mediated carcinogenic process.
Tobacco smoking and chewing has also been found to be associated with increased risk of cervical malignancy. Major
classes of carcinogens present in tobacco and tobacco smoke are converted into DNA-reactive metabolites by
cytochrome P450 (CYP)-related enzymes, several of which display genetic polymorphism. Individual susceptibility
to cancer is likely to be modified by the genotype for enzymes involved in the activation or detoxification of
carcinogens in tobacco and repair of DNA damage. Polymorphisms in the carcinogenmetabolizing enzymes are
thought to play a role in cancer susceptibility in humans. Associations of polymorphisms with cancer risk will be
especially important in cases where there are known exposures to chemical carcinogens such as with tobacco
smoking, high intake of food mutagens and industrial exposures. HPV infection, through the modulation of cellular
xenobiotic metabolizing enzymes, may play a role in the ability of cells to handle environmental carcinogens.
INTRODUCTION
Research in relation to the etiology of cervical
cancer has made substantial progress in the last
two decades both in scientific and operational
terms. For decades the epidemiological profile of
women with cervical cancer was recognized as
suggestive of a sexually transmitted process and
several infectious agents were proposed over
the years including syphilis, gonorrhea, Chlamy-
dia Trachomatis and type 2 Herpes Simplex Virus.
The development of technology to detect the
presence of Human Papilloma Virus (HPV) DNA
in cellular specimens in the early 1980s made
possible the establishment of a definite etio-
logical role for HPV in cervical cancer (Bosch et
al. 2002). The association of HPV with cervical
cancer has provided the background and the scie-
ntific justification for improving screening pro-
grams and for developing HPV vaccines (Bosch
et al. 2002). In many countries, HPV is the most
common sexually transmitted infection (STI) and
cervical cancer remains the second most common
cancer among women worldwide. In countries
where screening is not implemented, cervical
cancer is still a major health problem and a
frequent cause of death (Bosch et al. 2002). In
India, carcinoma of the uterine cervix accounts
for about 26% of female cancers, resulting in
about 95,000 women developing the disease
annually (Jayant et al. 1995). Thus we have 1/6th
of the world’s population and 1/3rd of the world’s
cervical cancer burden. Although high risk HPV
infection has been identified as the primary
etiological agent for cervical cancer, various co-
factors such as tobacco derived carcinogens,
inhalation of air contaminated through the combu-
stion of coal and kitchen smoke have also been
reported to be associated with cervical cancer.
Interindividual genetic differences in suscepti-
bility to various carcinogens are important host
factors associated with human cancer. It is thus
possible that variations in oncogenes, tumor
suppressor genes or xenobiotic metabolizing
genes may influence cervical carcinogenesis.
HUMAN  PAPILLOMA  VIRUS (HPV)
Papilloma viruses are epitheliotropic viruses
present in the skin and mucosa of several animals.
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In humans, more than 70 types have been
described (Zur Hausen H 1996). Recognized as
sexually transmitted agents, HPVs are believed
to be a contributing etiological factor in genital
cancers including carcinoma of the uterine cervix.
The association between HPV infection and
cervical neoplasia has been reported to satisfy
all accepted criteria for assessing casuality from
epidemiologic studies (Kaufman et al. 1997; Villa
1997; Zehbe and Wilander 1997). Mucosal and
genital HPVs, consisting of about 30 types, are
divided into low risk (HPVs 6, 11, 42, 43, and 44)
and high risk (HPVs 16, 18, 31, 33, 35, 45, 51, 52
and 56), according to their presence in malignant
lesions of the cervix (Lowy et al. 1994). Recognized
initially as sexually transmitted agents, HPVs are
now considered human carcinogens (N Munoz
2000). Numerous epidemiological studies indicate
a casual relationship between HPV infection and
cervical neoplasia (Milde-Langosch et al. 2000).
Functionally high-risk HPV infection contributes
to carcinogenesis and tumor progression predo-
minantly through the actions of two viral onco-
genes, E6 and E7. These oncogenes are consis-
tently expressed in cervical cell lines and in
human cancers (Milde-Langosch et al. 2000,
McMurray et al. 2001). Both of these oncogenes
interact with and inhibit the activities of critical
components of cell cycle regulatory systems, in
particular E6 with p53 and E7 with Rb (Milde-
Langosch et al. 2000, McMurray et al. 2001, Philips
et al. 1999). The E7 protein interacts with pRB
and inactivates this cellular protein (Dyson et al.
1989). As a consequence, E2F transcription factor
is released from pRB-E2F complex, leading to
transcriptional activation of several genes
involved in cell proliferation (Sellers et al. 1997).
Binding of the E6 protein to the p53 promotes
the degradation of the latter through a ubiquitin-
dependant proteolysis system. Also of signi-
ficance is that on completion of the degradation
of p53 by the ubiquitin-dependant proteolysis
system, the E6 protein is free to interact again
with remaining p53 molecules, leading to further
degradation of the latter (Scheffner 1998). These
events are summarized in Figure 1.
HPV Variants
The E6 and E7 genes have been studied in
different patient populations and a number of
variants have been described (Ginnoudis et al.
2001; Nindl et al. 1999;  Xu et al. 2001; Van Duin
et al. 2000). It can be classified into more than 40
variants and may be related to differences in
progression of squamous intraepithelial lesions.
The definition of an E6 variant is based on the
departure from an original prototype first isolated
from an invasive cervical carcinoma in Germany
(Ginnoudis et al. 2001). These variants have also
been geographically mapped to different areas
of the world based on sequence variations of the
E6, L1, L2, and long control regions (LCRs)
(Yamada et al. 1997). Studies from our laboratory
provided the first report on HPV 16 E6 and E7
gene variations from India and provide evidence
for the association of specific E6 gene variants
with the risk of cervical cancer. That these
particular variants may contribute to increased
risk and/or severity of cervical carcinoma is
supported by in vitro studies demonstrating that
differences exist in the immortalizing activity,
transforming potential and rate/extent of p53
degradation of the different HPV 16 variants (Pillai
et al. 2002).
P53 Polymorphisms
Genetic polymorphism is of significance in
cancer because the polymorphic variants are
thought to affect any one of the following features
in disease progression, i.e., they possess varia-
tion in metabolism of carcinogens and drugs, alter
risk from exposure, alter effectiveness of therapy,
or variation may play a role in disease. While E6
variants may be important in contributing to
increased severity of cervical cancer, polymor-
phisms of other host cellular proteins, such as
p53 and p73, may also play an as yet undefined
role in modulating the E6-mediated carcinogenic
process (Zehbe et al. 2001; Park et al. 2001). P53
is a tumor suppressor gene that responds to
genotoxic stress such as DNA damage and hypo-
xia and is considered the “guardian of the
genome” (Lane 1992) and was designated
“molecule of the year” in 1993 (Culotta and
Koshland 1993). It maintains genomic integrity
by arresting cell cycle progression or by inducing
apoptosis (Sidransky and Hollstein 1996; Soussi
and Beroud 2001). A p53 polymorphism in codon
72 has been described, which encodes either
arginine or proline residues. Interestingly, the fre-
quency of the arginine allele increases propor-
tionally to the latitude, while the proline allele
shows an inverse effect, i.e., it is more frequent
in Black populations, and the arginine allele pre-
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dominates among Caucasians (Beckman et al.
1994). It has been observed that the p53 arginine
variant is more susceptible to HPV E6 mediated
degradation than the proline variant. Individuals
homozygous for the arginine allele had a 7 times
higher chance to bear an HPV associated SCC of
the cervix than heterozygous proline/arginine
women (Storey et al. 1998). This sensitivity of
the Arginine variant could thus be clinically
important, as it has been clearly established that
p53 degradation is an important feature of HPV
associated tumors. However, subsequent analy-
ses performed in the similar and different
populations were contradictory making the issue
controversial (Rosenthal et al. 1998; Giannoudis
et al. 1999; Minaguchi et al. 1998). The two
previous pilot studies from India were also con-
tradictory. One report from Western India showed
evidence for increased risk of Arginine variant
(Saranath et al. 1999), while the other report from
Northern India found no evidence for increased
risk (Das et al. 1999). Our study, which included
various stages of pre-malignant cervical lesions
found no evidence of increased risk for progre-
ssion associated with Arginine homozygosity in
any of these subgroups (Pillai et al. 2002).
Tobacco
Tobacco smoking (either active or passive)
and chewing has also been found to be asso-
ciated with increased risk of cervical malignancy
(Parazzini et al. 1998; Daling et al. 1996). Nicotine,
cotinine and tobacco specific nitosamines have
been detected in cervical mucus of smokers and
those exposed to tobacco smoke (Prokopczyk et
al. 1997; McCann et al. 1992). DNA adducts of
aromatic compounds, have been reported to be
found with increased frequency in the cervical
epithelium of smokers compared to non-smokers
(Simons et al. 1993). Reports also showed that
women with exposure to wood smoke had a higher
risk of cervical neoplasia (Velema et al 2002).
Smoking may predispose a woman to the develop-
ment of cervical cancer by lowering the immune
surveillance at the cellular level also (Prokopczyk
et al. 1997; Mc Cann et al. 1992). Tobacco use is
causally associated with cancers of the lung,
larynx, mouth, esophagus, kidneys, urinary tract,
and possibly, breast. Major classes of carci-
nogens present in tobacco and tobacco smoke
are converted into DNA-reactive metabolites by
cytochrome P450 (CYP)-related enzymes, several
of which display genetic polymorphism.
Individual susceptibility to cancer is likely to be
modified by the genotype for enzymes involved
in the activation or detoxification of carcinogens
in tobacco and repair of DNA damage.
The mechanism by which PAHs such as
B[a]P interact with DNA, activate oncogenes,
and initiate the carcinogenic process involves
the formation of bay-region diolepoxides as the
major ultimate carcinogens. B[a]P is converted
into phenolic metabolites and B[a]P-7,8-diol by a
CYP-mediated process. Secondary metabolism,
mainly involving epoxide hydrolase and other
CYP isoforms, leads to the formation of the highly
reactive (+)-anti-BPDE. Several carcinogens
present in tobacco smoke are inactivated by
GSTs. The most frequently studied carcinogenic
PAH diolepoxide, BPDE, is a relatively good
substrate for GSTM1, M2, and M3 and better
still for GSTP1 (Bartsch et al. 2000). Because
tobacco carcinogens, ROS, and lipid peroxidation
products are likely to be substrates for GSTT1 or
M1, the extent of DNA damage and ultimately
the cancer risk may be affected by polymorphic
CYPs and GST detoxifying enzymes (Brockmoller
et al. 1998;  Nair et al. 1999).
Xenobiotic Metabolizing Enzyme (XME) Gene
Polymorphisms
Polymorphisms of genes involved in metabo-
lism of various endogenous and exogenous
carcinogens are relatively common in most popu-
lations. Generally carcinogens are oxidized to
reactive intermediates by phase I enzymes (eg.
CYPs), while phase II enzymes like glutathione
S-transferases (GST) generally mediate the
conjugation of water soluble moieties (such as
glutathione) to these reactive metabolites, render-
ing them harmless (Miller et al. 2001).
P450 cytochromes (CYP) are enzymes, which
catalyze the insertion of one atom of molecular
oxygen into a substrate. This is a typical reaction
of activation (phase I) which converts indirect
carcinogens into active electrophiles capable of
interacting with the biological macromolecules
DNA, RNA and proteins. CYP are coded by genes
of the CYP super family (Pavanello et al. 2000).
Glutathione S-transferases(GSTs) are one of the
major groups of detoxifying enzymes. Each GST
has distinct catalytic properties: conjugation with
glutathione, peroxidation and isomerization. The
cytosolic GSTs known until now belong to five
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different classes, are coded by atleast five gene
families and according to their primary amino acid
sequence, are called GST, classes α, µ, π, σ and θ
(Hayes et al. 1995).
Reactive metabolites that are not detoxified
may react with DNA to form DNA adducts which,
if not required, may eventually produce somatic
mutations and cancer. Of great interest in the
study of xenobiotic metabolism is the existence
of polymorphisms in animal model systems and
humans in which a large percentage of the alleles
of a particular gene are inactive (Gonzalez et al.
1994). Polymorphisms have been found in the
P450s and many phase II enzymes. In humans,
P450 polymorphisms are known to affect drug
therapy. Polymorphisms in the carcinogen-
metabolizing enzymes are thought to play a role
in cancer susceptibility in humans. Associations
of polymorphisms with cancer risk will be
especially important in cases where there are
known exposures to chemical carcinogens such
as with tobacco smoking, high intake of food
mutagens and industrial exposures (Caporaso et
al. 1995). It has been reported that HPV infection,
through the modulation of cellular xenobiotic
metabolizing enzymes, may play a role in the ability
of cells to handle environmental carcinogens
(Chen et al. 1999). Two genetic polymorphisms
of the CYP1A1 gene have been reported to be
associated with differences in the activity of the
enzyme aryl-hydrocarbon hydroxylase (AHH)
activity (H Autrup 2000) - an isoleucine to valine
substitution in exon 7 at the Nco I restriction site
(m2 polymorphism) and a thymine/cytosine point
mutation in the Msp1 restriction site (m1
polymorphism). The m2 (valine variant) displays
a two fold higher catalytic activity compared to
the wild type enzyme (H Autrup 2000). The signi-
ficance of these polymorphisms in carcinogenesis
is still unclear. The homozygous m2 poly-
morphism has been shown to strongly correlate
to lung cancer incidence among Japanese
although such dramatic results were not obtained
for Caucasians (Merchand et al. 1998). We had
earlier reported increased frequency of the m2
polymorphism in oral cancer patients with a long
history of tobacco use (T T Sreelekha et al. 2001).
Two previous studies on cervical cancer have
shown the importance of CYP1A1 polymor-
phisms. Women from Hawaii who were homozy-
gous for the CYP1A1 Msp variant allele (m1) had
an odds ratio of 3.4 of having cervical intraepi-
thelial lesions compared to women homozygous
for the wild allele (Goodman et al. 2001). However
Kim and colleagues did not find this association
in Korean women (Kim et al. 2000). Women with
m1 and m2 CYP1A1 polymorphisms and with
prolonged exposure to firewood smoke, tobacco
smoke or tobacco products will therefore have
higher levels of reactive metabolites capable of
causing DNA damage, in addition to a pre-
existing HPV infection. Studies conducted from
our laboratory show that subjects who were HPV
16 positive had an odds ratio of 3.0 (95%
Confidence Interval = 1.8 to 4.8) and 2.9 (95%
Confidence Interval = 1.8 to 4.6) of having a m1
and m2 polymorphism respectively (Pillai 2004,
data submitted). A recent report has provided
epidemiological evidence for the significant
increased risk of cervical carcinoma in HPV
infected women having prolonged exposure to
firewood smoke (Velema et al. 2002). We have
also observed that deletion of both GSTM1 and
GSTT1 was significant in cases compared to
controls. Unlike in the case of the CYP1A1 m1
and m2 variants, there was a moderate risk of
GSTM1 deletion in relation to age (Odds Ratio =
1.8, 95% Confidence Interval = 1.17 to 2.77). No
such association was evident in the case of
GSTT1. There was also an elevated risk for
women who were HPV positive of having GSTM1
and GSTT1 deletions (Odds Ratio = 1.6, 95%
Confidence Interval = 1.1 to 2.5 for GSTM1 and
Odds Ratio = 1.7, 95% Confidence Interval = 0.9
to 2.9).
CONCLUSION
It is obvious therefore that the genetic poly-
morphisms in metabolic enzymes may play a role
in development of cervical cancer and more
importantly may act as a co-factor in HPV asso-
ciated carcinogenesis. Cancer occurring in HPV
infected tissue can take fifteen to twenty years
to develop. During this intervening period,
increased chemical carcinogen exposure coupled
with inefficient clearing owing to genetic poly-
morphisms of xenobiotic metabolizing enzymes
can be a significant factor. In India, which has a
high incidence of HPV associated cancer, as well
as in many developing countries the disease is
associated with poor socioeconomic conditions.
Such women are often exposed to a wide range
of carcinogens including those derived from
tobacco use, prolonged and sustained inhalation
of smoke from kitchen firewood use and possibly
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the increased exposure to pesticides from work-
ing in the agricultural sector. It is thus clear that
large population studies are required in specific
populations to determine the biological properties
of natural E6 gene variants and eventually to
define the molecular mechanisms involved in HPV
oncogenecity.
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